【摘要】 目的观察地塞米松缓释微粒植入前房内对控制糖尿病性年龄相关性白内障人工晶状体植入术后炎症的作用。方法对60例糖尿病性年龄相关性白内障患者行小切口非超声乳化人工晶状体植入术,其中30例植入地塞米松缓释微粒,另30例为对照组。观察术后1、3、7d房水混浊和纤维蛋白渗出及膜形成情况。结果植入地塞米松缓释微粒组明显轻于对照组,两组差异具有显著性(P<0.05)。结论地塞米松缓释微粒植入前房控制术后炎症安全、有效、可靠。更多还原

【Abstract】 Objective To observe effects of Dexamethason (DXM) slow-releasing granules placed into anterior chamber on inflammation control after intraocular lens (IOL) implantation for diabetic age-related cataract. Methods For 60 cases of diabetic age-related cataract, non-phacoemulsification cataract extraction and IOL implantation were performed, on 30 of which DXM slow-releasing granules were placed into anterior chamber at the same time and the other 30 as controls. Acqueous opacity, fibroprotein exudates and membrane formation were observed at 1, 3 and 7 day postoperatively. Results Inflammation was significantly milder in the treatment group than in the control (P<0.05). Conclusion Placement of DXM slow-releasing granules in anterior chamber is a safe and effective method to control inflammation after IOL implantation for diabetic age-related cataract.更多还原